Successful use of infliximab in a patient with neuro‐Behçet’s disease

Ábalos-Medina, Gracia María; Sánchez‐Cano, Daniel; Ruiz‐Villaverde, Gonzalo; Ruíz‐Villaverde, Ricardo; Flores, S. Quirosa; Álvarez, Enrique Raya

doi:10.1111/j.1756-185x.2009.01420.x

Cited by 18 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infliximab was also administered in patients with neuro-Behçet refractory to high doses of steroids combined with cyclosporine, azathioprine, or MTX [Giardina et al 2011; Licata et al 2003; Ribi et al 2005; Sarwar et al 2005; Fujikawa et al 2007; Borhani Haghighi and Safari, 2008; Kikuchi et al 2008; Pipitone et al 2008; Abalos-Medina et al 2009]. The infliximab dose most commonly used was 3–5 mg/kg administered at 0, 2, and 6 weeks and every 6–8 weeks.…”

Section: Biologics and Monoclonal Therapymentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

115

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

Section: Biologics and Monoclonal Therapymentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

115

101

View full text Add to dashboard Cite

show abstract

“…IFN-α, as well as the newer anti-TNF agents infliximab, adalimumab, and etanercept, have also been used successfully [153][154][155][156], while combination therapy with anti-TNF agents and conventional immunosuppression may be more effective [157]. Thus, official EULAR recommendations propose their use for refractory cases (grade 3C and 3D) [150].…”

Section: Behçet's Disease (Bd)mentioning

confidence: 99%

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

et al. 2016

View full text Add to dashboard Cite

Neurological involvement is relatively common in the majority of systemic autoimmune diseases and may lead to severe morbidity and mortality, if not promptly treated. Treatment options vary greatly, depending on the underlying systemic pathophysiology and the associated neurological symptoms. Selecting the appropriate therapeutic scheme is further complicated by the lack of definite therapeutic guidelines, the necessity to differentiate primary neurological syndromes from those related to the underlying systemic disease, and to sort out adverse neurological manifestations caused by immunosuppressants or the biological agents used to treat the primary disease. Immunotherapy is a sine qua non for treating most, if not all, neurological conditions presenting in the context of systemic autoimmunity. Specific agents include classical immune modulators such as corticosteroids, cyclophosphamide, intravenous immunoglobulin, and plasma exchange, as well as numerous biological therapies, for example antitumor necrosis factor agents and monoclonal antibodies that target various immune pathways such as B cells, cytokines, and co-stimulatory molecules. However, experience regarding the use of these agents in neurological complications of systemic diseases is mainly empirical or based on small uncontrolled studies and case series. The aim of this review is to present the state-of-the-art therapies applied in various neurological manifestations encountered in the context of systemic autoimmune diseases; evaluate all treatment options on the basis of existing guidelines; and compliment these data with our personal experience derived from a large number of patients.

show abstract

“…In Spain, 17 relapsed neuro-Behçet disease was reported in a patient at age 52, characterised by headache and unilateral facial weakness. On MRI there were multiple T2 hyperintense lesions in both cerebral hemispheres.…”

Section: Brief Communicationsmentioning

confidence: 99%

Use of infliximab and other biologics in Behçet disease

Fernando

Herkes

2014

Internal Medicine Journal

View full text Add to dashboard Cite

Behçet disease is a multisystem vasculitis characterised by recurrent oral ulceration in conjunction with other manifestations. Neurological involvement or neuro-Behçet disease is not common, but typically affects young men at its onset between the ages of 20 and 40 with significant long-term morbidity and mortality. There is substantial case literature to support the use of tumour necrosis factor antagonists, notably infliximab, in the treatment of neuro-Behçet disease.

show abstract

Successful use of infliximab in a patient with neuro‐Behçet’s disease

Cited by 18 publications

References 15 publications

Update on the therapy of Behçet disease

Update on the therapy of Behçet disease

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

Use of infliximab and other biologics in Behçet disease

Contact Info

Product

Resources

About